Literature DB >> 10501682

[Psychiatric side effects during adjuvant therapy with interferon-alphain patients with malignant melanoma. Clinical evaluation as well as diagnostic and therapeutic possibilities].

M Schäfer1, T Messer, U Wegner, M H Schmid-Wendtner, M Volkenandt.   

Abstract

Interferon-alpha (IFN-alpha) is of high interest in the adjuvant treatment of malignant melanoma. During long term treatment, psychiatric side effects play an important role and not infrequently lead to reduction or discontinuation of therapy. Most common are sleeping disturbance, agitation, weariness, sleepiness, irritability, social withdrawal and depression, which most often develop during the first three months of the therapy. Also more severe side effects may occur, like delirium, organic depression, psychotic episodes and organic personality change, which in some patients may even lead to suicidal thoughts or suicide attempts, which is illustrated in two case reports. Therapeutic intervention depend to the severity of side effects. Moderate depressive syndromes may successfully be treated by antidepressive drugs like serotonin reuptake inhibitors (SSRI), which may even allow continuation of IFN-alpha therapy. In patients with severe depression or organic personality changes with increased risk of suicide, immideate discontinuation of IFN-alpha therapy is mandatory and treatment in a psychiatric hospital must be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501682     DOI: 10.1007/s001050050976

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  [Suicidal behavior in dermatology].

Authors:  W Harth; A Hillert; B Hermes; K Seikowski; V Niemeier; R W Freudenmann
Journal:  Hautarzt       Date:  2008-04       Impact factor: 0.751

2.  IFN-α-2a (Interferon) and ribavirin induced suicidal attempt in a patient of chronic HCV: A rare case report.

Authors:  Deep Inder; H S Rehan; Madhur Yadav; Seema Manak; Pawan Kumar
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.